Balancing omega-6 and omega-3 fatty acids in ready-to-use therapeutic foods (RUTF) by Brenna, J Thomas et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Balancing omega-6 and omega-3 fatty acids in ready-to-use therapeutic foods (RUTF)
Brenna, J Thomas; Akomo, Peter; Bahwere, Paluku; Berkley, James A; Calder, Philip C;
Jones, Kelsey D; Liu, Lei; Manary, Mark; Trehan, Indi; Briend, André
Published in:
B M C Medicine
DOI:
10.1186/s12916-015-0352-1
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Brenna, J. T., Akomo, P., Bahwere, P., Berkley, J. A., Calder, P. C., Jones, K. D., ... Briend, A. (2015).
Balancing omega-6 and omega-3 fatty acids in ready-to-use therapeutic foods (RUTF). B M C Medicine, 13,
[117]. https://doi.org/10.1186/s12916-015-0352-1
Download date: 03. Feb. 2020
Medicine for Global Health
Brenna et al. BMC Medicine  (2015) 13:117 
DOI 10.1186/s12916-015-0352-1COMMENTARY Open AccessBalancing omega-6 and omega-3 fatty acids in
ready-to-use therapeutic foods (RUTF)
J Thomas Brenna1, Peter Akomo2, Paluku Bahwere3, James A Berkley4,5, Philip C Calder6, Kelsey D Jones4,7, Lei Liu1,
Mark Manary8, Indi Trehan8,9 and André Briend10,11*Abstract
Ready-to-use therapeutic foods (RUTFs) are a key component of a life-saving treatment for young children who
present with uncomplicated severe acute malnutrition in resource limited settings. Increasing recognition of the
role of balanced dietary omega-6 and omega-3 polyunsaturated fatty acids (PUFA) in neurocognitive and immune
development led two independent groups to evaluate RUTFs. Jones et al. (BMC Med 13:93, 2015), in a study in BMC
Medicine, and Hsieh et al. (J Pediatr Gastroenterol Nutr 2015), in a study in the Journal of Pediatric Gastroenterology
and Nutrition, reformulated RUTFs with altered PUFA content and looked at the effects on circulating omega-3
docosahexaenoic acid (DHA) status as a measure of overall omega-3 status. Supplemental oral administration of
omega-3 DHA or reduction of RUTF omega-6 linoleic acid using high oleic peanuts improved DHA status, whereas
increasing omega-3 alpha-linolenic acid in RUTF did not. The results of these two small studies are consistent with
well-established effects in animal studies and highlight the need for basic and operational research to improve fat
composition in support of omega-3-specific development in young children as RUTF use expands.
Please see related article: http://www.biomedcentral.com/1741-7015/13/93
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Ready-to-use therapeutic foods (RUTFs) form the basis
of the nutritional management of uncomplicated severe
acute malnutrition (SAM), administered to millions of
children worldwide every year [1]. RUTFs are intended
as the sole food for several weeks during the rapid
catch-up growth phase of treatment. Therefore, their
nutritional composition must be complete and appropri-
ate to support all aspects of growth and development.
The conventional recipe for RUTFs leads to a high en-
ergy density food made with a peanut base with added
powdered milk, sugar, and fat, with 45% to 60% of the
energy derived from fat. Commodity peanuts and pre-
dominant vegetable oils from which RUTFs are com-
monly made contain a high omega-6 linoleic acid (LA)* Correspondence: andre.briend@gmail.com
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unless otherwise stated.content relative to essential fatty acid requirements and
negligible omega-3 alpha-linolenic acid (ALA) as sources
of omega-6 and omega-3 fatty acids, respectively. LA
and ALA are the dominant forms of the two polyunsat-
urated fatty acid (PUFA) families acquired from plant
foods, particularly vegetable oils. Their primary function
is to serve as substrates for endogenous metabolism,
which converts them to long chain PUFAs (LC-PUFA).
Best known among these are omega-6 arachidonic
acid (AA) and omega-3 eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). Omega-6 LA and AA are
seldom, if ever, limiting in the diet of otherwise well-
nourished free living humans, while EPA and particularly
DHA levels are known to be limiting from human stud-
ies that show DHA supplements improve status and
function. Neural tissue membranes are particularly rich
in DHA, accumulating perinatally, and both EPA and
DHA have roles in immune function and modulation of
inflammation. They can be consumed through foods of
marine origin (e.g., fish, shellfish), but these are often
expensive and/or prone to rapid spoilage, a property. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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shelf-life under ambient environmental conditions.
Scores of studies show that developing animals, de-
prived of omega-3 fatty acids using peanut and similar
omega-3 fatty acid-deficient oils during development,
grow normally but have functional deficits. These in-
clude poor maze navigation performance, aggression,
poor impulse control, and poor balance, to name a few,
as well as a myriad of biochemical deficits [2]. This is
due, in part, to replacement of the major structural fatty
acid in the brain, omega-3 DHA, by an abnormal
amount of the analogous omega-6 fatty acid docosapen-
taenoic acid, leading to neurocognitive deficits [2].
RUTFs do have marginal amounts of omega-3 ALA de-
livered by including an oil such as soybean or rapeseed
oil with small amounts of ALA; normally, such oils con-
tain more omega-6 LA and thus result in an RUTF
which is out of balance with respect to the child’s sole
nutritional source of the two essential fatty acid families.
Beyond this, effects of the tissue omega-6-omega-3 bal-
ance on inflammation and blood clotting are well recog-
nized, and recent work has implicated them in pain
sensitivity, which likely has repercussions in psycho-
logical well-being [3,4].
While RUTFs are recognized as the major contributor
to children’s recovery from SAM, increasing recognition
of support of normal development has led to more care-
ful consideration of oil composition.
Balancing polyunsaturated fatty acids
Ample clinical evidence from well-nourished infants in
developed countries is available to recommend an op-
tional, adequate intake level of omega-3 DHA in infant
artificial formulas to support development of neural tis-
sue [5], confirming the idea that a properly functioning
brain cannot be built without a dietary supply ofTable 1 Comparison of the plasma phospholipid fatty acid ch
(Jones et al. [8]) vs. those that decrease LA and increase ALA
Intake (% wt
Jones et al. [8], BMC Medicine 2015
n = 20 per group LA
Control S-RUTF 14.9
F-RUTF 14.4
Hsieh et al. [9], JPGN 2015
Control, n = 38; HO-RUTF, n = 43
Control C-RUTF 21.3
HO-RUTF 13.1
Jones et al. [8]: From entry DHA drops non-significantly from baseline with a 4.7-fol
oil supplemented (F) RUTF. Hsieh et al. [9]: DHA drops dramatically in control (C); th
weight of fatty acids.omega-3 fatty acids and balanced omega-6 fatty acids,
especially LA [6]. Unlike other omega-3 LC-PUFAs,
circulating DHA levels in adults are unresponsive to
supplementation with any precursor, including ALA,
although some response has been observed in young
infants [7].
Two recently completed clinical studies were first at-
tempts to address the balance of omega-6 and omega-3
fatty acids in RUTFs, with primary endpoints being cir-
culating LC-PUFA status. In a study in BMC Medicine,
Jones et al. [8] increased omega-3 fatty acids against a
background of constant omega-6 LA in two different
ways. A test RUTF with 4.7-fold more omega-3 ALA,
the DHA precursor from flaxseed oil (F-RUTF, Table 1),
was provided to one experimental group; a second
group received that test RUTF, along with EPA-DHA-
containing fish oil (FFO-RUTF) from capsules [8].
Circulating DHA successfully increased with fish oil
supplementation, as expected from many trials with
preformed DHA.
In another study, Hsieh et al. [9] reduced omega-6 LA
and increased omega-3 ALA, facilitated in part using
high oleic peanuts to yield 13% of the total fatty acids
from each of LA and ALA (HO-RUTF), with a similar
total PUFA content to the control (C-RUTF) [9]. The
two studies had a different ‘standard’ RUTF used as con-
trol, with a higher LA and a lower ALA content in the
study from Hsieh et al. [9] compared to the study from
Jones et al. [8]. The experimental RUTFs in both studies
had similar LA contents (13.1% vs. 14.4%) but differed in
the ALA content (13.1% vs. 6.2%; Table 1).
Both studies reported plasma phospholipid DHA, a
form that is receptor-transported into the brain, at 28
days of treatment. The Jones et al. [8] study showed that
both control and F-RUTF decreased DHA status, by −11%
and −21%, respectively, although these differences fromanges for treatments that exclusively increase ALA
(Hsieh et al. [9])
) Plasma phospholipid DHA (% wt)
ALA Basal 28 d Diff (%)
1.3 2.51 2.23 −11% n.s.
6.2 2.63 2.08 −21% n.s.
0.4 3.24 2.43 −25% P = 0.04
13.1 2.84 2.96 4% n.s.
d increase in ALA from flax with no change in LA for both standard (S) and flax
e drop in LA in high oleic (HO) prevents the decrease. Units are percent by
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tion, Hsieh et al. [9], using a larger sample size, showed a
significant decrease in their control group (−25% in DHA
with C-RUTF). This decrease was avoided in their experi-
mental group (HO-RUTF, +4% increase, not significant),
indicating that the form of DHA transported most effi-
ciently to the brain remained stable through the initial
recovery period.
Interpretation in the context of LC-PUFA nutrition
The results of the two studies are consistent with the hy-
pothesis that standard RUTF results in a decline in
DHA status. The two experimental groups were very
similar in their LA content and differed only in ALA
content. However, the difference in ALA between the
two experimental diets (13.1% vs. 6.23%) is unlikely to
explain the results as human and animal studies show
that no amount of any omega-3 precursor – ALA, stear-
idonic acid, EPA, or omega-3 docosapentaenoic acid –
improves DHA status [7]. Differences in other nutrients
may play a role, including mineral status, which influ-
ences function of the iron-containing desaturases re-
quired for endogenous synthesis of DHA [10,11].
Reduction of omega-6 LA intake, as in the experimen-
tal group in the Hsieh et al. [9] study, has been observed
to increase DHA status in at least three human studies
[12] as expected from decades of animal studies. The in-
take range for effects is not well established in humans,
especially malnourished children, and it is likely to differ
based on age and physiological state, among other fac-
tors. Importantly, the amount of omega-6 LA required
to prevent frank deficiency symptoms in otherwise well-
nourished infants is less than 1% of energy but with seed
oils it is often more than 10-fold this amount.
Both studies raise and attempt to address the serious
issue of omega-3 adequacy in RUTF for severely mal-
nourished children. Both studies demonstrated the safety
and acceptability of the experimental RUTFs. Neither
study was designed to identify a formulation producing
optimal DHA status or measured neurodevelopment. It
has long been known that omega-6 grows brawn, while
omega-3 grows brains [6]. Although neither study was
powered to detect effects on recovery from SAM, there
is every reason to believe that oil formulations altering
the relative proportions of the major fatty acids LA, ALA,
and oleic, among others, will support energy needs.
Conclusions
These studies both point to the vital need for trials of
RUTFs with balanced PUFA content in multiple loca-
tions using a harmonized methodology, assessing linear
growth, neurodevelopment, and infectious disease epi-
sode endpoints. LA reduction well below 13% can be
achieved with high oleic, low LA peanuts. Novel sourcesof preformed DHA as supplements should also be con-
sidered, but if included directly in RUTF are likely to in-
crease cost substantially and/or reduce shelf-life; the
study by Jones et al. [8] highlighted a potential issue with
the shelf-life for RUTFs with an elevated ALA content, a
concern with any strategy that raises PUFA levels. In
contrast, high oleic, low LA oils were developed to be
more stable than their conventional higher PUFA con-
tent counterparts.
Until such studies are available, the need for further
improvements should not distract from the fact that
RUTFs are currently a life-saving intervention despite
concerns over the decline in DHA status. Expanded
coverage and improved delivery of therapeutic feeding
services is a vital need.
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